Dyne Therapeutics Inc (DYN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.22B
Last updated: Nov 17, 2026 at 11:05 AM ET
Dyne Therapeutics Inc (DYN) Stock Forecast
Analysts expect Dyne Therapeutics (DYN) to earn -$3.90 per share in the fiscal year ending Dec 31, 2026. Of 17 analysts, 15 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.06, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 17.6% |
| Buy | 12 | 70.6% |
| Hold | 1 | 5.9% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 5.9% |
- Consensus
- Buy
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$3.90
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$3.54
- EPS consensus, revenue $54.33M
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.90 | -$4.00 to -$3.83 | 9 | N/A | N/A | 15 |
| Dec 31, 2027 | -$3.54 | -$4.53 to -$2.75 | 13 | $54.33M | N/A | 15 |
Quarterly Estimates
The EPS consensus falls from -$0.99 for the quarter ending Dec 31, 2026 to -$1.00 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.99 | -$1.06 to -$0.89 | 17 | N/A | N/A | 16 |
| Mar 31, 2027 | -$1.00 | -$1.08 to -$0.91 | 6 | $3.00M | $125000 to $8.95M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
| Quarter ending Mar 31, 2027 | 1 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.55.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.90 | -$3.53 | -$3.55 | -$3.55 | -$3.55 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.54 | -$3.31 | -$3.34 | -$3.33 | -$3.26 | N/A |
| Quarter ending Mar 31, 2027 | -$1.00 | -$0.84 | -$0.84 | -$0.80 | -$0.80 | N/A |
Frequently Asked Questions About DYN
What is the DYN stock forecast?
Consensus analyst estimates put Dyne Therapeutics's EPS at -$3.90 for the fiscal year ending Dec 31, 2026. The consensus rating from 17 analysts is Buy.
How do analysts rate DYN stock?
Of 17 analysts covering Dyne Therapeutics, 3 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DYN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.90, with estimates from -$4.00 to -$3.83 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.54, with estimates from -$4.53 to -$2.75 from 13 analysts.
What revenue do analysts expect from Dyne Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $54.33M.
How many analysts cover DYN?
17 analysts rate Dyne Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DYN pages: Overview, Earnings, Forecast, Financials, Competitors